Role of steroids in the treatment of diabetic macular edema

International Ophthalmology Clinics

Volumn 49, Issue 2, 2009, Pages 121-134

  Kuo, Chih Hung ^a   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; PLACEBO; STEROID; TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; LASER COAGULATION; LENS DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA DETACHMENT; REVIEW; STEROID THERAPY; VITREOUS HEMORRHAGE; ANIMAL; DIABETIC RETINOPATHY; DOSE RESPONSE; EXPERIMENTAL DIABETES MELLITUS; INJECTION; RETINA MACULA EDEMA; TREATMENT OUTCOME; VITREOUS BODY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR EDEMA; TREATMENT OUTCOME; VITREOUS BODY;

EID: 67650246081     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31819fcce8     Document Type: Review

References (61)

1. Kohner E. Diabetic retinopathy. Clin Endocrinol Metab. 1977;6:345-375.
2. Rothova A, Suttorp-van Schulten M, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332-336. (Pubitemid 26113585)
3. Chen S, Lochhead J, Patel C, et al. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol. 2004;88:154-155. (Pubitemid 38091385)
4. Klein R, Klein B, Moss S, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. Ophthalmology. 1995;102:7-16.
5. Adamis A. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-365.
6. Speiser P, Gittelsohn A, Patz A. Studies on diabetic retinopathy, III: influence of diabetes on intramural pericytes. Arch Ophthalmol. 1968;80:332-337.
7. Schroder S, Palinski W, Schmid-Schonbein G. Activated monocytes and granulocytes, capillary nonperfusion and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81-100.
8. Del Maschio A, Zanetti A, Corada M, et al. Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol. 1996;135:497-510. (Pubitemid 26359342)
9. Adamis A, Shima D. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118. (Pubitemid 40365933)
10. Lefer D, McLeod D, Merges C, et al. Immunolocalization of ICAM-1 (CD54) in the posterior eye of sickle cell and diabetic patients. Invest Ophthalmol Vis Sci. 1993;34:1206.
11. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006;168:235-244. (Pubitemid 43062576)
12. Kowluru RA, Odenbach S. Role of interleukin-1 beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci. 2004;45:4161-4166. (Pubitemid 39411175)
13. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95-103.
14. Powell E, Field R. Diabetic retinopathy in rheumatoid arthritis. Lancet. 1964;2:17-18.
15. Heiss J, Papavassiliou E, Merrill M, et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest. 1996;98:1400-1408. (Pubitemid 26322065)
16. Felinski E, Antonetti D. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30:949-957. (Pubitemid 43154689)
17. Nauck M, Karakiulakis G, Perruchoud A, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315. (Pubitemid 28131129)
18. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46:1440-1444. (Pubitemid 41685887)
19. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816. (Pubitemid 11199134)
20. Sturman R, Laval J, Sturman M. Subconjunctival triamcinolone acetonide. Am J Ophthalmol. 1966;61:155-166.
21. Coles R, Krohn D, Breslin H, et al. Depo-Medrol in treatment of inflammatory diseases. Am J Ophthalmol. 1962;54:407-411.
22. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol. 1974;92:149-154.
23. Tano Y, Sugita G, Abrams G, et al. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131-136. (Pubitemid 10160115)
24. McCuen B, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91:785-788. (Pubitemid 11078533)
25. Hida T, Chandler D, Arena J, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195. (Pubitemid 16136575)
26. Wilson C, Berkowitz B, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Am J Ophthalmol. 1992;110:1155-1159.
27. Edelman J, Lutz D, Castro M. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80:249-258.
28. Penfold P, Gyory J, Hunyor A, et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol. 1995;23:293-298. (Pubitemid 26025647)
29. Jonas J, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427. (Pubitemid 32768624)
30. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57-61. (Pubitemid 36401766)
31. Grover D, Li T, Chong C. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;1:CD005656. (Pubitemid 351807600)
32. Sutter F, Simpson J, Gillies M. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044-2049. (Pubitemid 39446723)
33. Gillies M, Sutter F, Simpson J, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-1538. (Pubitemid 44292310)
34. Diabetic Retinopathy Clinical Research Network. Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-1459.
35. Ciulla T, Walker J, Fong D, et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15:211-220. (Pubitemid 38638866)
36. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103:1796-1806.
37. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-224. (Pubitemid 38183217)
38. Chan C, Mohamed S, Shanmugam M, et al. Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. Br J Ophthalmol. 2006;90:1137-1141. (Pubitemid 44351145)
39. Gillies M, Islam A, Zhu M, et al. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol. 2007;91:1323-1326. (Pubitemid 47492866)
40. Gillies M, Simpson J, Billson F, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336-340. (Pubitemid 38314193)
41. Gillies M, Simpson J, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667-673. (Pubitemid 36554469)
42. Jonas J, Degenring R, Kreissig I, et al. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol. 2004;138:1054-1055. (Pubitemid 40040030)
43. Scott I, Flynn H. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27:10-12. (Pubitemid 46095824)
44. Bhavsar A, Ip M, Glassman A. The Risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144:454-456. (Pubitemid 47336932)
45. Beer P, Bakri S, Singh R, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686. (Pubitemid 36520063)
46. Jonas J. Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol. 2002;86:1066. (Pubitemid 34953629)
47. Schatz H, Madeira D, McDonald H, et al. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-1551.
48. Maeshima K, Utsugi-Sutoh N, Otani T, et al. Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina. 2004;24:507-511. (Pubitemid 39079874)
49. Dowler J, Sehmi K, Hykin P, et al. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology. 1999;106:663-668. (Pubitemid 30194302)
50. Funatsu H, Yamashita H, Noma H, et al. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg. 2002;28:1355. (Pubitemid 37022444)
51. Lovestam-Adrian M, Agardh E. Photocoagulation of diabetic macular oedema - complications and visual outcome. Acta Ophthalmol Scand. 2000;78:667-671.
52. Larsson J, Kifley A, Zhu M, et al. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone-Data from a randomized, placebo controlled clinical trial. Acta Ophthalmol. 2008. [Epub ahead of print].
53. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766-785.
54. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695-702. (Pubitemid 41455312)
55. Lam DSC, Chan CKM, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology. 2007;114:2162-2167.e1. (Pubitemid 350181096)
56. Kang S, Sa H, Cho H, et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124:653-658.
57. Qaum TX, Xu Q, Joussen A, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413. (Pubitemid 32848873)
58. Cunningham EJ, Adamis A, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
59. van Wijngaarden P, Coster D, Williams K. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293:1509-1513. (Pubitemid 40393297)
60. Pearson P, Levy B, Comstock T, et al. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial. Invest Ophthalmol Vis Sci. 2006;47.
61. Kuppermann B, Blumenkranz M, Haller J, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309-317. (Pubitemid 46425557)